HIROAKI Taniguchi, Ph. D.

Associate Professor, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences

Field of Interest

Neuroscience, Cancer Molecular Biology, Health Sciences, Reproductive Biology, Epigenetics, and Transcriptional Gene Regulation, Genome Editing

Research Outcome

45 JCR publications, H-index=15, 992 citations

Selected Scientific Achievements

He demonstrated that a transcription factor Hamlet (Prdm3 in mammals) controls the epigentic state of Notch target promoters and olfactory neuron cel fate on the fly. This study was published in Nature Neurosci and recommended by the Faculty of 1000 Biology (also introduced in Sci. Signal and Nat Neurosci). He has also demonstrated the functional importance of the noncoding and coding of mutations in Japanese liver cancer (published in Nature Genetics). He has expertise in transcriptional gene regulation in the gonad and neuronal system (Mol.Endocrinol. 2005; Endocrinology 2005; J.Mol.Endocrinol. 2009, BBRC2017). Additionally, he has many years of experience in broad areas of research including proteomics (Mol.Cell.Biol. 2013; Sci.Rep. 2015; BBRC 2016), epigenetics (Nat.Neurosci. 2012; Bioessays 2014), and cancer genome biology (Oncogene 2015; Sci.Rep. 2016; Nat.Genet. 2016).

Current Research Projects
1)NCN Opus 13 (2018-2021): UMO-2017/25/B/NZ5/02762 PI
2)Horizon 2020 (2019-2023): H2020-SFS-2018-2020 SEP-210522343 (BovReg) Work Package 6 Leader

Organizational Activity, Dissemination and Others

He obtained a Ph. D. from Laval University (Faculty of Medicine, Canada) in 2007. After his training at several highly qualified research institutes (McGill University, RIKEN Brain Science Institute), he was appointed as an assistant professor (2012-2014) and adjunct lecturer (2015-2016) at Doshisha University in Kyoto, Japan. He is currently appointed as a visiting scientist at Doshisha University (2014-). He organized the Riken-Research Administorator meeting that was supported by the RIKEN presidential fund, and he served as a scientific observer at the Japan-UK Symposium Neuronal Epigenetics Meeting. He collaborates with researchers from different countries (Japan, China, Bangladesh, India, England, Germany, US, and Canada).

Recent Publications (2016-) and Patents

Publications)

1.Leszczyński P, Śmiech M, Teeli AS, Haque E, Viger R, Ogawa H, Pierzchała M, Taniguchi H. Deletion of Prdm3 gene causes neuronal differentiation deficiency in P19 cells. Int J Mol Sci. 2020 in press

2.Haque E, Karim MR, Salam Teeli A, Śmiech M, Leszczynski P, Winiarczyk D, Parvanov ED, Atanasov AG, Taniguchi H. Molecular Mechanisms Underlying Hepatocellular Carcinoma Induction by Aberrant NRF2 Activation-Mediated Transcription Networks: Interaction of NRF2-KEAP1 Controls the Fate of Hepatocarcinogenesis.Int J Mol Sci. 2020 21(15):5378. doi: 10.3390/ijms21155378.

3.Taniguchi H, Fujimoto A, Kono H, Furuta M, Fujita M, Nakagawa H.  Loss-of-function mutations in Zn-finger DNA-binding domain of HNF4A cause aberrant transcriptional regulation in liver cancer.  Oncotarget. 2018 9(40):26144-26156. doi: 10.18632/oncotarget.25456.

4.Taniguchi H, Okamuro S, Kohji M, Waku T, Kubo K, Hatanaka A, Sun Y, Chowdhury AM, Fukamizu A, Kobayashi A. Possible roles of the transcription factor Nrf1 (NFE2L1) in neural homeostasis by regulating the gene expression of deubiquitinating enzymes. Biochem.Biophys.Res.Commun. 2017   Jan 11. pii: S0006-291X (17) 30047-5. doi: 10.1016 / j.bbrc.2017.01.038.

5.Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat.Genet. 2016; 48: 500-509. 

Patents)

1.A method to prevent epithelial to mesenchymal transition and cancer metastasis(JP 2015-053282 ;Patented)

2.METHOD AND DEVICE FOR ARRANGING CELLS USING LASER (WO/2016/039397; Published)

Links to professional profiles

https://www.researchgate.net/profile/Hiroaki_Taniguchi4